A Multi-targeted Drug Candidate with Dual Anti-HIV and Anti-HSV Activity

PLoS Pathogens

Volumn 9, Issue 7, 2013, Pages

  Balzarini, Jan ^a   Andrei, Graciela ^a   Balestra, Emanuela ^b   Huskens, Dana ^a   Vanpouille, Christophe ^c   Introini, Andrea ^c   Zicari, Sonia ^c   Liekens, Sandra ^a   Snoeck, Robert ^a   Holý, Antonín ^d   Perno, Carlo Federico ^b   Margolis, Leonid ^c   Schols, Dominique ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADEFOVIR; BETA CHEMOKINE; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; DNA POLYMERASE; PYROPHOSPHATE; RNA DIRECTED DNA POLYMERASE; STEVENAGE; TENOFOVIR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CD4+ T LYMPHOCYTE; CELL CULTURE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG ACTIVITY; FEMALE; FLOW CYTOMETRY; HERPES SIMPLEX; HERPES VIRUS INFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; KERATINOCYTE; LYMPHOID TISSUE; MACROPHAGE; MESSENGER RNA SYNTHESIS; MIXED INFECTION; MONOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; UPREGULATION; VIRUS ENTRY; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 84884794379     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003456     Document Type: Article

References (54)

1. Blower S, Ma L, (2004) Calculating the contribution of herpes simplex virus type 2 epidemics to increasing HIV incidence: treatment implications. Clin Infect Dis 39, Suppl 5: S240-S247.
2. Corey L, (2007) Synergistic copathogens-HIV-1 and HSV-2. N Engl J Med 356: 854-856.
3. Buvé A, (2010) Can we reduce the spread of HIV infection by suppressing herpes simplex virus type 2 infection? F1000 Med Rep 2: 41.
4. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, et al. (2006) Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20: 73-83.
5. Martinelli E, Tharinger H, Frank I, Arthos J, Piatak M Jr, et al. (2011) HSV-2 infection of dendritic cells amplifies a highly susceptible HIV-1 cell target. PLoS Pathog 7: e1002109.
6. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, et al. (1998) Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 280: 61-66.
7. Lehner T, Hussain L, Wilson J, Chapman M, (1991) Mucosal transmission of HIV. Nature 353: 709.
8. Spira AI, Marx PA, Patterson BK, Mahoney J, Koup RA, et al. (1996) Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 183: 215-225.
9. Moriuchi M, Moriuchi H, Williams R, Straus SE, (2000) Herpes simplex virus infection induces replication of human immunodeficiency virus type 1. Virology 278: 534-540.
10. Balzarini J, Holý A, Jindrich J, Naesens L, Snoeck R, et al. (1993) Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother 37: 332-338.
11. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, et al. (1977) Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci US A 74: 5716-5720.
12. Nagot N, Ouédraogo A, Foulongne V, Konaté I, Weiss HA, et al. (2007) Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 356: 790-799.
13. Delany S, Mlaba N, Clayton T, Akpomiemie G, Capovilla A, et al. (2009) Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 23: 461-469.
14. Ludema C, Cole SR, Poole C, Chu H, Eron JJ, (2011) Meta-analysis of randomized trials on the association of prophylactic acyclovir and HIV-1 viral load in individuals coinfected with herpes simplex virus-2. AIDS 25: 1265-1269.
15. Mugwanya K, Baeten JM, Mugo NR, Irungu E, Ngure K, et al. (2011) High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial. J Infect Dis 204: 1912-1917.
16. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
17. Cates W Jr, (2010) After CAPRISA 004: time to re-evaluate the HIV lexicon. Lancet 376: 495-496.
18. Lisco A, Vanpouille C, Tchesnokov EP, Grivel JC, Biancotto A, et al. (2008) Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe 4: 260-270.
19. Andrei G, Lisco A, Vanpouille C, Introini A, Balestra E, et al. (2011) Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe 10: 379-389.
20. De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, et al. (1987) Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 8: 261-272.
21. Pauwels R, Balzarini J, Schols D, Baba M, Desmyter J, et al. (1988) Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother 32: 1025-1030.
22. Heijtink RA, De Wilde GA, Kruining J, Berk L, Balzarini J, et al. (1993) Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res 21: 141-153.
23. Lehner T, Hussain L, Wilson J, Chapman M, (1991) Mucosal transmission of HIV. Nature 353: 709.
24. Grivel JC, Margolis L, (2009) Use of human tissue explants to study human infectious agents. Nat Protoc 4: 256-269.
25. Balzarini J, Schols D, Van Laethem K, De Clercq E, Hocková D, et al. (2007) Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidines. J Antimicrob Chemother 59: 80-86.
26. Thurman AR, Doncel GF, (2012) Herpes simplex virus and HIV: genital infection synergy and novel approaches to dual prevention. Int J STD AIDS 23: 613-619.
27. Jiang Y, Jolly PE, (1999) Effect of beta-chemokines on human immunodeficiency virus type 1 replication, binding, uncoating, and CCR5 receptor expression in human monocyte-derived macrophages. J Hum Virol 2: 123-132.
28. Cremer I, Vieillard V, De Maeyer E, (2000) Retrovirally mediated IFN-beta transduction of macrophages induces resistance to HIV, correlated with up-regulation of RANTES production and down-regulation of C-C chemokine receptor-5 expression. J Immunol 164: 1582-1587.
29. Bergmeier LA, Wang Y, Lehner T, (2002) The role of immunity in protection from mucosal SIV infection in macaques. Oral Dis 8, Suppl 2: 63-68.
30. Dudley DM, Wentzel JL, Lalonde MS, Veazey RS, Arts EJ, (2009) Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques. J Virol 83: 5067-5076.
31. Ahmed RK, Makitalo B, Karlen K, Nilsson C, Biberfeld G, et al. (2002) Spontaneous production of RANTES and antigen-specific IFN-gamma production in macaques vaccinated with SHIV-4 correlates with protection against SIVsm challenge. Clin Exp Immunol 129: 11-18.
32. Introini A, Vanpouille C, Lisco A, Grivel JC, Margolis L, (2013) Interleukin-7 facilitates HIV-1 transmission to cervico-vaginal tissue ex vivo. PLoS Pathog 9: e1003148.
33. Taub DD, Lloyd AR, Conlon K, Wang JM, Ortaldo JR, et al. (1993) Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 177: 1809-1814.
34. Werry TD, Wilkinson GF, Willars GB, (2003) Cross talk between P2Y2 nucleotide receptors and CXC chemokine receptor 2 resulting in enhanced Ca2+ signaling involves enhancement of phospholipase C activity and is enabled by incremental Ca2+ release in human embryonic kidney cells. J Pharmacol Exp Ther 307: 661-669.
35. Huskens D, Vermeire K, Profy AT, Schols D, (2009) The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1. Antiviral Res 84: 38-47.
36. Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, et al. (2011) Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 25: 957-966.
37. Kedzierska K, Crowe SM, (2001) Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother 12: 133-150.
38. Kedzierska K, Crowe SM, Turville S, Cunningham AL, (2003) The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages. Rev Med Virol 13: 39-56.
39. Lehner T, Wang Y, Cranage M, Tao L, Mitchell E, et al. (2009) Up-regulation of beta-chemokines and down-modulation of CCR5 co-receptors inhibit simian immunodeficiency virus transmission in non-human primates. Immunology 99: 569-577.
40. Pastori C, Weiser B, Barassi C, Uberti-Foppa C, Ghezzi S, et al. (2006) Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. Blood 107: 4825-4833.
41. Heredia A, Amoroso A, Davis C, Le N, Reardon E, et al. (2003) Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci U S A 100: 10411-10416.
42. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, Cost M, et al. (2010) In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One 5: e9310.
43. Schwartz JL, Rountree R, Kashuba A, et al. (2009) A multi-compartment, single and multiple dose pharmacokinetic study of the candidate vaginal microbicide 1% tenofovir gel. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 19-22 July 2009, Abstract LBDECO3.
44. Andrei G, van den Oord J, Fiten P, Opdenakker G, De Wolf-Peeters C, et al. (2005) Organotypic epithelial raft cultures as a model for evaluating compounds against alphaherpesviruses. Antimicrob Agents Chemother 49: 4671-4680.
45. Montefiori DC, (2009) Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol 485: 395-405.
46. Balzarini J, Pannecouque C, De Clercq E, Aquaro S, Perno C-F, et al. (2002) Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonates. Antimicrob Agents Chemother 46: 2185-2193.
47. Holý A, Votruba I, Masojídková M, Andrei G, Snoeck R, et al. (2002) 6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity. J Med Chem 45: 1918-1929.
48. Andrei G, Snoeck R, De Clercq E, Esnouf R, Fiten P, et al. (2000) Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene. J Gen Virol 81: 639-648.
49. Brand G, Schiavano GF, Balestra E, Tavazzi B, Perno C-F, et al. (2001) The potency of acyclovir can be markedly different in different cell types. Life Sci 69: 1285-1290.
50. Biancotto A, Brichacek B, Chen SS, Fitzgerald W, Lisco A, et al. (2009) A highly sensitive and dynamic immunofluorescent cytometric bead assay for the detection of HIV-1 p24. J Virol Methods 157: 98-101.
51. Aquaro S, Menten P, Struyf S, Proost P, Van Damme J, et al. (2001) The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages. J Virol 75: 4402-4406.
52. Huskens D, Férir G, Vermeire K, Kehr JC, Balzarini J, et al. (2010) Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile. J Biol Chem 285: 24845-24854.
53. Ying C, Holý A, Hocková D, Havlas Z, De Clercq E, et al. (2005) Novel acyclic nucleoside phosphonate analogues with potent anti-hepatitis B virus activities. Antimicrob Agents Chemother 49: 1177-1180.
54. Herman BD, Votruba I, Holý A, Sluis-Cremer N, Balzarini J, (2010) The acyclic 2,4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization. J Biol Chem 285: 12101-12108.